128 related articles for article (PubMed ID: 15359291)
1. Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission.
Lichtenstein DL; Wold WS
Cancer Gene Ther; 2004 Dec; 11(12):819-29. PubMed ID: 15359291
[TBL] [Abstract][Full Text] [Related]
2. Effect of hypoxia on Ad5 infection, transgene expression and replication.
Shen BH; Hermiston TW
Gene Ther; 2005 Jun; 12(11):902-10. PubMed ID: 15690062
[TBL] [Abstract][Full Text] [Related]
3. Replication-selective oncolytic viruses in the treatment of cancer.
Everts B; van der Poel HG
Cancer Gene Ther; 2005 Feb; 12(2):141-61. PubMed ID: 15472714
[TBL] [Abstract][Full Text] [Related]
4. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
5. Isolated limb perfusion: a novel delivery system for wild-type p53 and fiber-modified oncolytic adenoviruses to extremity sarcoma.
Hannay J; Davis JJ; Yu D; Liu J; Fang B; Pollock RE; Lev D
Gene Ther; 2007 Apr; 14(8):671-81. PubMed ID: 17287860
[TBL] [Abstract][Full Text] [Related]
6. Insulated hsp70B' promoter: stringent heat-inducible activity in replication-deficient, but not replication-competent adenoviruses.
Rohmer S; Mainka A; Knippertz I; Hesse A; Nettelbeck DM
J Gene Med; 2008 Apr; 10(4):340-54. PubMed ID: 18265421
[TBL] [Abstract][Full Text] [Related]
7. Oral delivery of replication-competent adenovirus vectors is well tolerated by SIV- and SHIV-infected rhesus macaques.
Gómez-Román VR; Grimes GJ; Potti GK; Peng B; Demberg T; Gravlin L; Treece J; Pal R; Lee EM; Alvord WG; Markham PD; Robert-Guroff M
Vaccine; 2006 Jun; 24(23):5064-72. PubMed ID: 16621178
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of human CD46 by adenovirus serotype 35 vectors.
Sakurai F; Akitomo K; Kawabata K; Hayakawa T; Mizuguchi H
Gene Ther; 2007 Jun; 14(11):912-9. PubMed ID: 17377598
[TBL] [Abstract][Full Text] [Related]
10. Heat shock and heat shock protein 70i enhance the oncolytic effect of replicative adenovirus.
Haviv YS; Blackwell JL; Li H; Wang M; Lei X; Curiel DT
Cancer Res; 2001 Dec; 61(23):8361-5. PubMed ID: 11731408
[TBL] [Abstract][Full Text] [Related]
11. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors.
Thomas MA; Spencer JF; La Regina MC; Dhar D; Tollefson AE; Toth K; Wold WS
Cancer Res; 2006 Feb; 66(3):1270-6. PubMed ID: 16452178
[TBL] [Abstract][Full Text] [Related]
12. Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy.
Lam JT; Kanerva A; Bauerschmitz GJ; Takayama K; Suzuki K; Yamamoto M; Bhoola SM; Liu B; Wang M; Barnes MN; Alvarez RD; Siegal GP; Curiel DT; Hemminki A
J Gene Med; 2004 Dec; 6(12):1333-42. PubMed ID: 15493039
[TBL] [Abstract][Full Text] [Related]
13. Concomitant use of Ad5/35 chimeric oncolytic adenovirus with TRAIL gene and taxol produces synergistic cytotoxicity in gastric cancer cells.
Chen L; Chen D; Gong M; Na M; Li L; Wu H; Jiang L; Qian Y; Fang G; Xue X
Cancer Lett; 2009 Nov; 284(2):141-8. PubMed ID: 19447545
[TBL] [Abstract][Full Text] [Related]
14. Viral and nonviral factors causing nonspecific replication of tumor- and tissue-specific promoter-dependent oncolytic adenoviruses.
Hurtado Picó A; Wang X; Sipo I; Siemetzki U; Eberle J; Poller W; Fechner H
Mol Ther; 2005 Apr; 11(4):563-77. PubMed ID: 15771959
[TBL] [Abstract][Full Text] [Related]
15. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
[TBL] [Abstract][Full Text] [Related]
16. A potent replicative delta-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms.
Delgado-Enciso I; Cervantes-García D; Martínez-Dávila IA; Ortiz-López R; Alemany-Bonastre R; Silva-Platas CI; Lugo-Trampe A; Barrera-Saldaña HA; Galván-Salazar HR; Coronel-Tene CG; Sánchez-Santillán CF; Rojas-Martínez A
J Gene Med; 2007 Oct; 9(10):852-61. PubMed ID: 17729237
[TBL] [Abstract][Full Text] [Related]
17. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
18. State-of-the-art human adenovirus vectorology for therapeutic approaches.
Gao J; Mese K; Bunz O; Ehrhardt A
FEBS Lett; 2019 Dec; 593(24):3609-3622. PubMed ID: 31758807
[TBL] [Abstract][Full Text] [Related]
19. Development of PEGylated adenovirus vector with targeting ligand.
Eto Y; Yoshioka Y; Mukai Y; Okada N; Nakagawa S
Int J Pharm; 2008 Apr; 354(1-2):3-8. PubMed ID: 17904316
[TBL] [Abstract][Full Text] [Related]
20. Overcoming maternal antibody interference by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of swine influenza virus.
Wesley RD; Lager KM
Vet Microbiol; 2006 Nov; 118(1-2):67-75. PubMed ID: 16939702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
